AR056846A1 - USO DE UN ANTAGONISTA DE CB1 PARA TRATAR EFECTOS SECUNDARIOS Y SíNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA - Google Patents
USO DE UN ANTAGONISTA DE CB1 PARA TRATAR EFECTOS SECUNDARIOS Y SíNTOMAS NEGATIVOS DE LA ESQUIZOFRENIAInfo
- Publication number
- AR056846A1 AR056846A1 ARP060105411A ARP060105411A AR056846A1 AR 056846 A1 AR056846 A1 AR 056846A1 AR P060105411 A ARP060105411 A AR P060105411A AR P060105411 A ARP060105411 A AR P060105411A AR 056846 A1 AR056846 A1 AR 056846A1
- Authority
- AR
- Argentina
- Prior art keywords
- schizophrenia
- negative symptoms
- antagonist
- combination
- secondary effects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion describe y reivindica un método para tratar déficits cognitivos en un paciente que padece esquizofrenia, mediante la administracion a dicho paciente de una cantidad terapéuticamente eficaz de un antagonista del receptor CB1 como se describe en esta memoria. En otro aspecto, esta invencion también describe y reivindica una combinacion de uno o más antagonistas del receptor CB1 y de uno o más agentes antipsicoticos utiles en el tratamiento de trastornos psiquiátricos. La combinacion de esta invencion proporciona resultados sinérgicos en los que la combinacion mejora los síntomas positivos y negativos de la esquizofrenia, la ganancia de peso y catalepsia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74843405P | 2005-12-08 | 2005-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056846A1 true AR056846A1 (es) | 2007-10-24 |
Family
ID=37964962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105411A AR056846A1 (es) | 2005-12-08 | 2006-12-07 | USO DE UN ANTAGONISTA DE CB1 PARA TRATAR EFECTOS SECUNDARIOS Y SíNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA |
Country Status (23)
Country | Link |
---|---|
US (1) | US20080221078A1 (es) |
EP (1) | EP1962834A2 (es) |
JP (1) | JP2009518423A (es) |
KR (1) | KR20080073737A (es) |
CN (1) | CN101321523A (es) |
AR (1) | AR056846A1 (es) |
AU (1) | AU2006321907A1 (es) |
BR (1) | BRPI0619541A2 (es) |
CA (1) | CA2632673A1 (es) |
CR (1) | CR9957A (es) |
DO (1) | DOP2006000273A (es) |
EC (1) | ECSP088505A (es) |
IL (1) | IL191888A0 (es) |
MA (1) | MA30090B1 (es) |
NO (1) | NO20082923L (es) |
PE (1) | PE20071092A1 (es) |
RU (1) | RU2008127491A (es) |
SV (1) | SV2008002929A (es) |
TN (1) | TNSN08205A1 (es) |
TW (1) | TW200803839A (es) |
UY (1) | UY29995A1 (es) |
WO (1) | WO2007067617A2 (es) |
ZA (1) | ZA200803924B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
AU2008307572A1 (en) * | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
PT2234966E (pt) * | 2007-12-18 | 2013-12-19 | Sanofi Sa | Derivados de azetidinas, sua preparação e sua aplicação em terapia |
FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
ES2886641T3 (es) | 2014-08-11 | 2021-12-20 | Angion Biomedica Corp | Inhibidores de citocromo P450 y sus usos |
CN107531631B (zh) | 2014-12-31 | 2021-09-03 | 安吉昂生物医药公司 | 用于治疗疾病的方法和药剂 |
MX2019002265A (es) | 2016-08-24 | 2019-10-30 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US7485732B2 (en) * | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
EP1663215A1 (en) * | 2003-09-02 | 2006-06-07 | Solvay Pharmaceuticals GmbH | Novel medical use of selective cb1- receptor antagonists |
WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
-
2006
- 2006-12-06 PE PE2006001558A patent/PE20071092A1/es not_active Application Discontinuation
- 2006-12-06 DO DO2006000273A patent/DOP2006000273A/es unknown
- 2006-12-07 AU AU2006321907A patent/AU2006321907A1/en not_active Abandoned
- 2006-12-07 RU RU2008127491/15A patent/RU2008127491A/ru not_active Application Discontinuation
- 2006-12-07 EP EP06839095A patent/EP1962834A2/en not_active Ceased
- 2006-12-07 BR BRPI0619541-5A patent/BRPI0619541A2/pt not_active IP Right Cessation
- 2006-12-07 CA CA002632673A patent/CA2632673A1/en not_active Abandoned
- 2006-12-07 WO PCT/US2006/046547 patent/WO2007067617A2/en active Application Filing
- 2006-12-07 AR ARP060105411A patent/AR056846A1/es not_active Application Discontinuation
- 2006-12-07 CN CNA2006800454370A patent/CN101321523A/zh active Pending
- 2006-12-07 KR KR1020087013697A patent/KR20080073737A/ko not_active Application Discontinuation
- 2006-12-07 JP JP2008544469A patent/JP2009518423A/ja not_active Abandoned
- 2006-12-08 TW TW095145876A patent/TW200803839A/zh unknown
- 2006-12-08 UY UY29995A patent/UY29995A1/es unknown
-
2008
- 2008-05-07 CR CR9957A patent/CR9957A/es not_active Application Discontinuation
- 2008-05-08 ZA ZA200803924A patent/ZA200803924B/xx unknown
- 2008-05-08 TN TNP2008000205A patent/TNSN08205A1/en unknown
- 2008-05-22 US US12/125,285 patent/US20080221078A1/en not_active Abandoned
- 2008-06-02 IL IL191888A patent/IL191888A0/en unknown
- 2008-06-06 SV SV2008002929A patent/SV2008002929A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008505A patent/ECSP088505A/es unknown
- 2008-06-25 NO NO20082923A patent/NO20082923L/no not_active Application Discontinuation
- 2008-06-26 MA MA31081A patent/MA30090B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20080221078A1 (en) | 2008-09-11 |
CR9957A (es) | 2008-09-22 |
UY29995A1 (es) | 2007-07-31 |
EP1962834A2 (en) | 2008-09-03 |
WO2007067617A2 (en) | 2007-06-14 |
SV2008002929A (es) | 2009-12-02 |
PE20071092A1 (es) | 2007-12-10 |
ZA200803924B (en) | 2009-10-28 |
RU2008127491A (ru) | 2010-01-20 |
JP2009518423A (ja) | 2009-05-07 |
ECSP088505A (es) | 2008-08-29 |
CN101321523A (zh) | 2008-12-10 |
TW200803839A (en) | 2008-01-16 |
KR20080073737A (ko) | 2008-08-11 |
BRPI0619541A2 (pt) | 2011-10-04 |
TNSN08205A1 (en) | 2009-10-30 |
AU2006321907A1 (en) | 2007-06-14 |
CA2632673A1 (en) | 2007-06-14 |
NO20082923L (no) | 2008-09-02 |
DOP2006000273A (es) | 2007-10-15 |
MA30090B1 (fr) | 2008-12-01 |
IL191888A0 (en) | 2009-08-03 |
WO2007067617A3 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056846A1 (es) | USO DE UN ANTAGONISTA DE CB1 PARA TRATAR EFECTOS SECUNDARIOS Y SíNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA | |
NI201100084A (es) | Antagonistas del receptor de orexina de isonicotinamida. | |
ME01532B (me) | Jedinjenja | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
ATE477252T1 (de) | Substituierte diazepane als antagonisten an orexinrezeptoren | |
UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
UY30253A1 (es) | Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina | |
JO3070B1 (ar) | عوامل لمعالجة إضطرابات تتضمن تعديل مستقبلات الريانودين | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
CO6251266A2 (es) | Antagonistas piridil piperidina del receptor de orexina | |
ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
CR10165A (es) | "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión" | |
CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
UY33206A (es) | Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4 | |
ECSP088619A (es) | Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva | |
ECSP10010409A (es) | INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 | |
ECSP034810A (es) | Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6 | |
PA8795701A1 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
UY29417A1 (es) | Agentes endoparasiticidas | |
NI200900073A (es) | Compuestos de carbamato para su uso en el tratamiento de la depresión. | |
PA8597501A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |